File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/hed.26018
- Scopus: eid_2-s2.0-85075733793
- PMID: 31778007
- WOS: WOS:000499024300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma
Title | Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma |
---|---|
Authors | |
Keywords | prognostication biomarker nasopharyngeal carcinoma plasma EBV DNA pitfalls |
Issue Date | 2020 |
Citation | Head and Neck, 2020, v. 42, n. 3, p. 446-455 How to Cite? |
Abstract | © 2019 Wiley Periodicals, Inc. Background: This study identifies potential pitfalls in incorporating plasma Epstein-Barr virus (EBV) DNA into the management of nasopharyngeal carcinoma (NPC). Methods: A total of 208 NPC patients without distant metastasis who received radical treatment and had measurements of EBV DNA at baseline, 8 weeks and 26 weeks postradiotherapy were analyzed. Prognostic and predictive values at each time-point were compared. Results: Risk stratification by pretreatment level failed to identify a poor prognostic group. Detectable EBV DNA at 8 weeks and 26 weeks postradiotherapy were both associated with significantly poorer 5-year disease-free survival (HR 0.30, P <.001 and HR 0.03, P <.001, respectively) and overall survival (HR 0.27, P =.009 and HR 0.03, P <.001, respectively). Eighty percentage had detectable EBV DNA at recurrence (53.3% for local only, 100% for regional only, and 100% for distant failure). Conclusions: Posttreatment EBV DNA, particularly at 26 weeks post-radiotherapy, has high prognostic and predictive values. Surveillance endoscopy/imaging are recommended for the detection of local recurrence. |
Persistent Identifier | http://hdl.handle.net/10722/282117 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 1.034 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, Edwin C.Y. | - |
dc.contributor.author | Hung, Jessica L.C. | - |
dc.contributor.author | Ng, Wai T. | - |
dc.date.accessioned | 2020-04-29T07:36:06Z | - |
dc.date.available | 2020-04-29T07:36:06Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Head and Neck, 2020, v. 42, n. 3, p. 446-455 | - |
dc.identifier.issn | 1043-3074 | - |
dc.identifier.uri | http://hdl.handle.net/10722/282117 | - |
dc.description.abstract | © 2019 Wiley Periodicals, Inc. Background: This study identifies potential pitfalls in incorporating plasma Epstein-Barr virus (EBV) DNA into the management of nasopharyngeal carcinoma (NPC). Methods: A total of 208 NPC patients without distant metastasis who received radical treatment and had measurements of EBV DNA at baseline, 8 weeks and 26 weeks postradiotherapy were analyzed. Prognostic and predictive values at each time-point were compared. Results: Risk stratification by pretreatment level failed to identify a poor prognostic group. Detectable EBV DNA at 8 weeks and 26 weeks postradiotherapy were both associated with significantly poorer 5-year disease-free survival (HR 0.30, P <.001 and HR 0.03, P <.001, respectively) and overall survival (HR 0.27, P =.009 and HR 0.03, P <.001, respectively). Eighty percentage had detectable EBV DNA at recurrence (53.3% for local only, 100% for regional only, and 100% for distant failure). Conclusions: Posttreatment EBV DNA, particularly at 26 weeks post-radiotherapy, has high prognostic and predictive values. Surveillance endoscopy/imaging are recommended for the detection of local recurrence. | - |
dc.language | eng | - |
dc.relation.ispartof | Head and Neck | - |
dc.subject | prognostication | - |
dc.subject | biomarker | - |
dc.subject | nasopharyngeal carcinoma | - |
dc.subject | plasma EBV DNA | - |
dc.subject | pitfalls | - |
dc.title | Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/hed.26018 | - |
dc.identifier.pmid | 31778007 | - |
dc.identifier.scopus | eid_2-s2.0-85075733793 | - |
dc.identifier.volume | 42 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 446 | - |
dc.identifier.epage | 455 | - |
dc.identifier.eissn | 1097-0347 | - |
dc.identifier.isi | WOS:000499024300001 | - |
dc.identifier.issnl | 1043-3074 | - |